Schrödinger, Inc. is a life sciences and materials discovery company that specializes in the application of physics-based computational platforms to accelerate drug discovery and advanced materials design. Founded in 1990 by Professor Richard A. Friesner, Schrödinger has developed a suite of proprietary software tools—such as Maestro for molecular modeling, Glide for molecular docking and Jaguar for quantum chemistry calculations—that enable scientists to predict molecular behavior with high accuracy. These platforms are deployed on-premises or via cloud-based subscriptions, catering to pharmaceutical, biotechnology and materials science clients worldwide.
Beyond its software offerings, Schrödinger collaborates with industry partners through research alliances, joint ventures and sponsored research agreements. Its integrated business model couples software licensing with contract research services, allowing clients to leverage Schrödinger’s computational expertise in target identification, lead optimization and materials property prediction. The company’s computational chemistry workflows have been used to support numerous drug candidates and novel materials initiatives, contributing to more efficient R&D pipelines and reduced experimental costs.
Headquartered in New York City, Schrödinger maintains additional offices in Europe and Asia to serve its global customer base. The company’s leadership team is led by President and Chief Executive Officer Dr. Ramy Farid, who brought extensive drug discovery experience from both industry and academia. Schrödinger’s board and scientific advisory committees include leaders from major pharmaceutical companies and academic institutions, reinforcing its commitment to advancing computational science in real-world applications.
Over its three decades of growth, Schrödinger has continuously expanded its platform capabilities, integrating machine learning techniques with physics-based methods to enhance predictive accuracy. This evolving technology stack supports a broad range of therapeutic areas—from oncology and central nervous system disorders to infectious diseases—while also enabling the design of high-performance materials for electronics, energy storage and beyond. As computational methods play an increasingly central role in research and development, Schrödinger remains at the forefront of the convergence between advanced modeling tools and life sciences innovation.
